Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil
Durvalumab as maintenance in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real World Data from an Expanded Access Program in Brazil
Carcinoma, Non-Small-Cell Lung
Describe real world data on PFS of patients treated with Durvalumab in stage III NSCLC in the EAP in Brazil, June of 2018
- To describe Overall response rate, defined as the proportion of patients who have a partial or complete response to durvalumab therapy., June of 2018|- To describe Overall survival at 3 years, defined as the time from start of durvalumab therapy to death from any cause., June of 2018|- To describe the sequence of lines of treatment in patients which have disease progression after durvalumab., June of 2018
Durvalumab as maintenance in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real World Data from an Expanded Access Program in Brazil